ReviewDiagnostics (Basel, Switzerland)2015
Circulating HMGB1 and RAGE as Clinical Biomarkers in Malignant and Autoimmune Diseases.
Review in Diagnostics (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Targeting High Mobility Group Box 1 in Subarachnoid Hemorrhage: A Systematic Review.International journal of molecular sciences · 2020Pooled it
- Macrophage pyroptosis drives luminal senescence and club-cell reprogramming in 5α-reductase inhibitor-treated prostatic hyperplasia.Experimental & molecular medicine · 2026Article
- Endothelial HMGB1-AIM2 axis worsens myocardial ischemia-reperfusion injury by regulating endothelial pyroptosis.Apoptosis : an international journal on programmed cell death · 2025Article
- High Mobility Group Box 1 (HMGB1): Molecular Signaling and Potential Therapeutic Strategies.Cells · 2024Review
- The Association of HMGB1 and RAGE Gene Polymorphisms with IgA Vasculitis.Biochemical genetics · 2024Article
- Insight into the Interplay of Gd-IgA1, HMGB1, RAGE and PCDH1 in IgA Vasculitis (IgAV).International journal of molecular sciences · 2024Article
- Article
- Immunogenic Biomarkers HMGB1 and sRAGE Are Potential Diagnostic Tools for Ovarian Malignancies.Cancers · 2023Article
- Inflammation and coagulation abnormalities via the activation of the HMGB1‑RAGE/NF‑κB and F2/Rho pathways in lung injury induced by acute hypoxia.International journal of molecular medicine · 2023Article
- HMGB1 in depression: An overview of microglial HMBG1 in the pathogenesis of depression.Brain, behavior, & immunity - health · 2023Review
- High-mobility group box 1 protein, receptor for advanced glycation end products and nucleosomes increases after marathon.Frontiers in physiology · 2023Article
- High mobility group box-1 levels may be associated with disease activity of Behcet's diseaseTurkish journal of medical sciences · 2021Article
- Increased GFAP concentrations in the cerebrospinal fluid of patients with unipolar depression.Translational psychiatry · 2021Article
- HMGB1 as a therapeutic target in disease.Journal of cellular physiology · 2021Review
- Soluble High Mobility Group Box 1 (HMGB1) Is a Promising Biomarker for Prediction of Therapy Response and Prognosis in Advanced Lung Cancer Patients.Diagnostics (Basel, Switzerland) · 2021Article
- Liquorice for pain?Therapeutic advances in psychopharmacology · 2021Review
- MiR-126-HMGB1-HIF-1 Axis Regulates Endothelial Cell Inflammation during Exposure to Hypoxia-Acidosis.Disease markers · 2021Article
- HMGB1 participates in LPS‑induced acute lung injury by activating the AIM2 inflammasome in macrophages and inducing polarization of M1 macrophages via TLR2, TLR4, and RAGE/NF‑κB signaling pathways.International journal of molecular medicine · 2020Article
- The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterations.Blood advances · 2019Article
- Significance of serum antibodies against HPV E7, Hsp27, Hsp20 and Hp91 in Iranian HPV-exposed women.BMC infectious diseases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High molecular group box 1 (HMGB1) is a highly conserved member of the HMG-box-family; abundantly expressed in almost all human cells and released in apoptosis; necrosis or by activated immune cells. Once in the extracellular space, HMGB1 can act as a danger associated molecular pattern (DAMP), thus stimulating or inhibiting certain functions of the immune system; depending on the "combinatorial cocktail" of the surrounding milieu. HMGB1 exerts its various functions through binding to a multitude of membrane-bound receptors such as TLR-2; -4 and -9; IL-1 and RAGE (receptor for advanced glycation end products); partly complex-bound with intracellular fragments like nucleosomes. Soluble RAGE in the extracellular space, however, acts as a decoy receptor by binding to HMGB1 and inhibiting its effects. This review aims to outline today's knowledge of structure, intra- and extracellular functions including mechanisms of release and finally the clinical relevance of HMGB1 and RAGE as clinical biomarkers in therapy monitoring, prediction and prognosis of malignant and autoimmune disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.